In conclusion, our study indicated that the adjuvant PD-1 inhibitor treatment was more effective than conventional therapy groups (IFN+OBS) in prolonging OS, RFS, and DMFS in Chinese patients with resected stage III acral and cutaneous melanoma, especially those with a heavy disease burden, stage IIIC/D, ulcerated, macrometastasis in the lymph nodes, or distant metastasis. The gene discussed is PDCD1; the disease is cutaneous melanoma.